Edwards Lifesciences Corp. agreed to pay $10 million in penalties linked to its 2024 acquisition of JC Medical, former subsidiary of Singapore-based Genesis MedTech.
The Federal Trade Commission’s complaint alleges that Edwards and Genesis intentionally structured the deal to avoid federal premerger filing requirements.
Genesis will also pay a $2 million penalty under the terms of the final judgement.
Shares in Edwards fell 2% to $90.03 apiece with a market cap of $51.8 billion (NYSE: EW).
Related links:
